Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04713982 · ClinicalTrials.gov registry record · Phase 2
Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease
A Phase 2 study of Huntington Disease, sponsored by Vanderbilt University Medical Center.
- Active
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT04713982: Active Phase 2 study of Huntington Disease, sponsored by Vanderbilt University Medical Center.
NCT04713982 is a Phase 2 study of Huntington Disease that is active but no longer recruiting, run by Vanderbilt University Medical Center. The registered enrollment target is 30 participants, below the 635-participant average among 35 other Huntington Disease trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04713982, a Phase 2 study of Huntington Disease, is active but no longer recruiting, sponsored by Vanderbilt University Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Examine the effects of deutetrabenazine on functional speech and gait impairment
Primary Outcome
SIT is a measure of speech intelligibility that requires the participant to read aloud 11 sentences that increase in length from 5 to 10 words. Speech intelligibility is indexed in terms of percent intelligible. This is determined by calculating the mean number of correct words transcribed from the SIT transcriptions by three unfamiliar listeners and dividing this by the total number of words in the 11-sentence sample.
Conditions Studied
Interventions
- DRUG Deutetrabenazine
Study Locations (1)
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2021-11-19 |
| Est. Completion | 2026-10-01 |
| Phase | Phase 2 |
What the registry record for NCT04713982 still lists
NCT04713982 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 635-participant average among 35 other Huntington Disease trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Huntington Disease appearing as the primary indexed condition, and to 1 intervention - of which Deutetrabenazine is the first listed.
NCT04713982 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT04713982 about?
NCT04713982 is a clinical study titled "Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease". Examine the effects of deutetrabenazine on functional speech and gait impairment
What is the current status of trial NCT04713982?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2021-11-19. Estimated completion is 2026-10-01.
What conditions does trial NCT04713982 study?
This clinical trial studies the following conditions: Huntington Disease.
What interventions are being tested in trial NCT04713982?
The interventions under investigation include: Deutetrabenazine (DRUG).
Who is sponsoring clinical trial NCT04713982?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04713982 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Huntington Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04713982's enrollment target sits among peer trials
30 26th of 35 higher than 10 of 35 other Huntington Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Huntington Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease
ACTIVE NOT RECRUITING · Phase 2
-
Creatine Safety and Tolerability in Premanifest HD: PRECREST
COMPLETED · Phase 2
-
Atomoxetine and Huntington's Disease
COMPLETED · Phase 2
-
Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease
COMPLETED · Phase 2
-
A Study of Pridopidine (ACR16) for the Treatment of Participants With Huntington's Disease
COMPLETED · Phase 2
-
Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI